“We delivered strong growth of approximately 15% in Portfolio Receipts in the third quarter of 2024 and are delighted to raise our full year guidance” said Pablo Legorreta, Royalty Pharma’s (RPRX) founder and Chief Executive Officer. “We also strengthened our portfolio by adding royalties on three innovative therapies over the last three months, increasing our Capital Deployment to approximately $1.2 billion in the third quarter and $2.6 billion year-to-date. Notably, two of these transactions were for synthetic royalties for $500 million in total, continuing the strong demand we are seeing for this attractive, flexible type of capital. Lastly, we are pleased with the progress of our portfolio as Voranigo and Cobenfy were recently approved by the FDA. Based on our robust deal pipeline, our leading position as the partner of choice in the royalty market and our efficient business model, I am confident that Royalty Pharma is well positioned to deliver attractive, compounding growth over the long term.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax
- Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
- Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
- Royalty Pharma price target lowered to $40 from $60 at Citi
- Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug